The World Bispecific & T‑Cell Engager Summit South Korea is Asia’s first and only industry‑dedicated forum focused on advancing bispecific antibodies and T‑cell engagers (TCEs), modalities that are redefining the therapeutic landscape for solid tumors and immune‑driven diseases. Propelled by landmark regulatory approvals such as tarlatamab and ivonescimab, bispecifics and TCEs have captured global interest for their ability to address previously unmet medical needs.

This inaugural summit brings together international experts and regional leaders for deep‑dive sessions on advanced engineering, co-stimulation strategies, antibody masking, conditional activation, and the design of trispecific and tetraspecific formats. The agenda also explores bispecific ADCs (bsADCs), novel target selection, TCE expansion into autoimmune disease, translational biology, and early clinical readouts shaping development priorities.

As South Korea positions itself as a rising global powerhouse in targeted therapeutics, this summit provides a vital forum for advancing first‑in‑class bispecific and TCE‑based therapies with the potential to transform patient outcomes worldwide.

One Pass, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs), Bispecifics, and T-cell engagers, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.

To know more visit: https://ter.li/bw174h